Biocept, Inc. (BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells or CTCs and circulating tumor DNA or ctDNA biomarker analysis, said it has been granted a patent in China for its microfluidic channel technology used to capture CTCs. The granted patent is the subject of Chinese Patent No. ZL200780032530.2, entitled, "Detection or Isolation of Target Molecules Using a Microchannel Apparatus."
This patent improves Biocept's ongoing East-Asia expansion strategy, that aims to increase the adoption of blood-based liquid biopsies to test for biomarkers associated with cancer and help inform patients and their physicians when making treatment decisions.
Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept, said, "The granting of this patent expands Biocept's international IP portfolio and positions the Company well in the Chinese market to be a potential leader in providing innovative technologies for capturing and analyzing circulating tumor cells."
For comments and feedback contact: editorial@rttnews.com
Business News